Keyphrases
Ovarian Cancer
100%
Mitochondria
100%
Platinum-based Chemotherapy
100%
Caspase
100%
Clinical Model
100%
Mitochondrium
100%
Patient-derived Xenograft
60%
Cisplatin-based Chemotherapy
60%
Combination Therapy
60%
Advanced Ovarian Cancer
40%
Death Pathway
40%
Cisplatin
40%
Sigma-2 Ligand
40%
Cancer Cell Selectivity
40%
Treatment Options
20%
Treatment Response
20%
Tumor
20%
Monotherapy
20%
Murine Model
20%
Survival Rate
20%
Cell Death
20%
Inducer
20%
Small Molecules
20%
Multiple Cell Lines
20%
Syngeneic
20%
Flow Cytometry
20%
Synergize
20%
Ovarian Cancer Cells
20%
Caspase-3
20%
Treatment Efficacy
20%
Combination Treatment
20%
Recurring
20%
Recurrent Ovarian Cancer
20%
Assay System
20%
Necropsy
20%
Promising Treatment
20%
Peptide Analogs
20%
Human Ovarian Cancer
20%
Tumor Cell Death
20%
Complete Resolution
20%
Caspase Activation
20%
Preclinical Development
20%
Pathway Activation
20%
Peptidomimetics
20%
Sigma-2 Receptor
20%
Drug Toxicity
20%
Cancer Targeting
20%
Preclinical Evaluation
20%
Targeting Peptide
20%
Cell Viability Assay
20%
Potential Drugs
20%
Syngeneic Mouse Model
20%
Tumor Growth Rate
20%
Off-target Toxicity
20%
Upfront Chemotherapy
20%
Medicine and Dentistry
Mitochondrion
100%
Ovarian Cancer
100%
Caspase
100%
Cisplatin
71%
Combination Therapy
57%
Malignant Neoplasm
42%
Xenograft
42%
Cell Death
28%
Conjugate
28%
Treatment Response
14%
Neoplasm
14%
In Vitro
14%
Monotherapy
14%
Tumor Cell
14%
Survival Rate
14%
Flow Cytometry
14%
Cell Line
14%
Ovarian Cancer Cell Line
14%
Tumor Progression
14%
Recurrent Ovarian Cancer
14%
Caspase 3
14%
Sigma 2 Opiate Receptor
14%
Cell Viability Assay
14%
Pre-Clinical Development
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Ovary Cancer
100%
Caspase
100%
Cisplatin
55%
Combination Therapy
44%
Malignant Neoplasm
33%
Neoplasm
22%
Tumor Growth
11%
Monotherapy
11%
Mouse Model
11%
Survival Rate
11%
Caspase 3
11%
Flow Cytometry
11%
Cell Viability
11%
Sigma 2 Opiate Receptor
11%
Viability Assay
11%